Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy

Zackary D Goff; Hugh Calkins

doi:10.1016/j.pcad.2019.04.001

Sudden death related cardiomyopathies - Hypertrophic cardiomyopathy

Prog Cardiovasc Dis. 2019 May-Jun;62(3):212-216. doi: 10.1016/j.pcad.2019.04.001. Epub 2019 Apr 17.

Authors

Zackary D Goff¹, Hugh Calkins²

Affiliations

¹ Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America.
² Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America; Division of Cardiology, Johns Hopkins University School of Medicine, Baltimore, MD, United States of America. Electronic address: hcalkins@jhmi.edu.

PMID: 31004609
DOI: 10.1016/j.pcad.2019.04.001

Abstract

Hypertrophic cardiomyopathy (HCM) is a form of inherited cardiomyopathy. Most individuals with HCM experience minimal symptoms throughout their lifetime. However, those with HCM are at risk of ventricular arrhythmias and sudden cardiac death (SCD), the most feared complication of HCM. Implantable cardioverter defibrillator (ICD) implantation has played a large role in transforming this disease from one with an ominous prognosis to one with mortality rates that are on par with the general public. Since the early 2000s, balance between SCD prevention and unnecessary ICD placement has been sought, this is reflected in the evolution of SCD risk stratification models for patients with HCM. This review discusses key concepts pertaining to HCM, with emphasis on prevention of SCD, and summarizes and compares the recommendations for ICD implantation in current guidelines.

Keywords: Cardiomyopathy; Hypertrophic cardiomyopathy; Sudden cardiac death.

Publication types

Review

MeSH terms

Arrhythmias, Cardiac / etiology
Cardiomyopathy, Hypertrophic / complications*
Cardiomyopathy, Hypertrophic / therapy
Death, Sudden, Cardiac / etiology
Death, Sudden, Cardiac / prevention & control*
Defibrillators, Implantable*
Humans
Risk Factors